US Bancorp’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

US Bancorp’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-68	Closed	-$1.57K	–	4173
2023 Q1	$1.57K	Buy	+68	New	+$1.62K	﹤0.01%	3812
2022 Q4	–	Sell	-84	Closed	-$2K	–	4314
2022 Q3	$2K	Hold	84	–	–	﹤0.01%	3892
2022 Q2	$1K	Buy	+84	New	+$1.32K	﹤0.01%	4042
2020 Q1	–	Sell	-5	Closed	–	–	3842
2019 Q4	$0	Sell	5 -12	-71%	-$65	﹤0.01%	3755
2019 Q3	$0	Hold	17	–	–	﹤0.01%	3703
2019 Q2	$0	Hold	17	–	–	﹤0.01%	3701
2019 Q1	$0	Hold	17	–	–	﹤0.01%	3675
2018 Q4	$0	Hold	17	–	–	﹤0.01%	3730
2018 Q3	$1K	Sell	17 -47	-73%	-$1.51K	﹤0.01%	3595
2018 Q2	$2K	Hold	64	–	–	﹤0.01%	3510
2018 Q1	$3K	Buy	64 +47	+276%	+$1.72K	﹤0.01%	3449
2017 Q4	$1K	Buy	+17	New	+$742	﹤0.01%	3566

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

US Bancorp's KDNY Position: Q2 2023 in Review

US Bancorp sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 68 shares — an estimated $1.57K sold.

US Bancorp first reported a position in KDNY in Q4 2017 and held it in 12 quarters. The position peaked at $3K in Q1 2018. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

US Bancorp reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 68 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.57K.
US Bancorp first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 12 quarters.
US Bancorp's Chinook Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2018.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.